Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 801–900 of 1,006
Glioblastoma: Imaging Genomic Mapping Reveals Sex-specific Oncogenic Associations of Cell Death
Colen, R. R., Wang, J., Singh, S. K., Gutman, D. A., & Zinn, P. O. (2014) · Radiology · doi:10.1148/radiol.14141800 · Cited by 77
The Ability of Versican to Simultaneously Cause Apoptotic Resistance and Sensitivity
LaPierre, D. P., Lee, D. Y., Li, S.-Z., Xie, Y., Zhong, L., Wang, S., Deng, Z., & Yang, B. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3610 · Cited by 79
“Because hypoxic conditions can induce apoptosis through the p53-associated pathway (16), the cells were treated with the hypoxia mimetics cobalt chloride (CoCl2) and desferrioxamine.”
MethodKomarova, E. A., & Gudkov, A. V. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00733-x · Cited by 81
Progress in cancer genetics: Lessons from pancreatic cancer
Goggins, M., Kern, S. E., Offerhaus, J. A., & Hruban, R. H. (1999) · Annals of Oncology · doi:10.1093/annonc/10.suppl_4.s4 · Cited by 70
“Hypoxia induces p53 and this induction can be mediated by HIF-la (hypoxia inducible factor 1 alpha) [32-35], suggesting that the hypoxia present in a cancer nodule selects for cells that have lost p53-mediated hypoxia-induced apoptosis.”
BackgroundStress signals induce transcriptionally inactive E2F-1 independently of p53 and Rb
O’Connor, D. J., & Lü, X. (2000) · Oncogene · doi:10.1038/sj.onc.1203540 · Cited by 75
“The p53 protein accumulates in cells exposed to hypoxia, and prolonged hypoxic conditions can induce p53 dependent apoptosis (Graeber et al., 1996).”
BackgroundGenealogy, expression, and molecular mechanisms in apoptosis
Dlamini, Z., Mbita, Z., & Zungu, M. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.08.005 · Cited by 84
Metastasis and stem cell pathways
Barnhart, B. C., & Simon, M. C. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9053-3 · Cited by 79
“Hypoxia contributes directly to the development of more aggressive cancer cells by exerting selective pressure on the tumor cell population which can survive decreased O2 and nutrient levels [5].”
Hoogsteen, I. J., Marres, H. A. M., Wijffels, K. I. E. M., Rijken, P. F. J. W., Peters, J. P. W., van den Hoogen, F. J. A., Oosterwijk, E., van der Kogel, A. J., & Kaanders, J. H. A. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.97.11.1 · Cited by 74
“(6) showed that hypoxia promotes the selection of tumor cell phenotypes with diminished apoptotic potential.”
BackgroundMendichovszky, I. A., & Jackson, A. (2011) · British Journal of Radiology · doi:10.1259/bjr/82292521 · Cited by 76
“A few studies suggested hypoxia-induced phenotypic changes, such as genomic instability, loss of apoptotic potential, alterations of gene expression, oncogene activation and induction of angiogenesis, are necessary conditions to malignant progression [14–20].”
BackgroundSystemic Metastasis in Glioblastoma May Represent the Emergence of Neoplastic Subclones
Park, C. C., Hartmann, C. J., Folkerth, R. D., Loeffler, J. S., Wen, P. Y., Fine, H. A., Black, P. M., Shafman, T. D., & Louis, D. N. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.12.1044 · Cited by 74
“For example, hypoxia encourages the emergence of clones that harbor TP53 mutations and have decreased apoptotic potential (34).”
BackgroundRegulation of BNIP3 in Normal and Cancer Cells
Lee, H., & Paik, S.-G. (2006) · Molecules and Cells · doi:10.1016/s1016-8478(23)12896-2 · Cited by 74
Apoptosis and chemoresistance in transgenic cancer models
Schmitt, C. A., & Lowe, S. W. (2001) · Journal of Molecular Medicine · doi:10.1007/s00109-001-0293-3 · Cited by 78
“The tumor microenvironment, characterized by tumor cells, endothelial, stromal, and infiltrating immune cells as well as nutrient supply and oxygen gradients within the tumor compartment modulate therapy effectiveness (for review see [ 19 , 20, 21, 22, 23]).”
BackgroundSelf-citationFibroblast heterogeneity in physiological conditions and fibrotic disease
Jelaska, A., Strehlow, D., & Korn, J. H. (1999) · Springer Seminars in Immunopathology · doi:10.1007/bf00870301 · Cited by 74
Liu, Y., Veena, C. K., Morgan, J. B., Mohammed, K. A., Jekabsons, M. B., Nagle, D. G., & Zhou, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m806744200 · Cited by 77
1,2Fucosyltransferase increases resistance to apoptosis of rat colon carcinoma cells
Goupille, C., Marionneau‐Lambot, S., Bureau, V., Hallouin, F., Meichenin, M., Rocher, J., & LePendu, J. (2000) · Glycobiology · doi:10.1093/glycob/10.4.375 · Cited by 74
“Resistance to apoptosis could be a factor of bad prognosis (Graeber et al., 1996).”
BackgroundThe p53 tumor suppressor: Critical regulator of life & death in cancer
Fisher, D. E. (2001) · APOPTOSIS · doi:10.1023/a:1009659708549 · Cited by 86
H3K9me3 facilitates hypoxia-induced p53-dependent apoptosis through repression of APAK
Olcina, M. M., Leszczyńska, K. B., Senra, J. M., Isa, N. F., Harada, H., & Hammond, E. M. (2015) · Oncogene · doi:10.1038/onc.2015.134 · Cited by 74
Galluzzo, M., Pennacchietti, S., Rosano, S., Comoglio, P. M., & Michieli, P. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36579 · Cited by 73
HIF-transcribed p53 chaperones HIF-1α
Madan, E., Parker, T. M., Pelham, C. J., Palma, A. M., Peixoto, M. L., Nagane, M., Chandaria, A., Tomás, A. R., Canas‐Marques, R., Henriques, V., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz766 · Cited by 81
Bacon, A. L., Fox, S., Turley, H., & Harris, A. L. (2007) · Oncogene · doi:10.1038/sj.onc.1209761 · Cited by 69
“…occur in more than 50% of all human cancers (Levine, 1997) and the higher malignancy of hypoxic tumours has been attributed to the ability of hypoxia to select for cells that are more resistant to apoptosis by virtue of their acquisition of p53 mutations (Graeber et al., 1996; Yu et al., 2002).”
BackgroundCalcium-dependent Interaction of S100B with the C-terminal Domain of the Tumor Suppressor p53
Delphin, C., Ronjat, M., Deloulme, J., Garin, G., Debüssche, L., Higashimoto, Y., Sakaguchi, K., & Baudier, J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.15.10539 · Cited by 73
Effects of p 53 mutations on apoptosis in mouse intestinal and human colonic adenomas
Fazeli, A., Steen, R. G., Dickinson, S., Bautista, D., Dietrich, W. F., Bronson, R. T., Bresalier, R. S., Lander, E. S., Costa, J. C., & Weinberg, R. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.19.10199 · Cited by 82
Role of programmed cell death in development
Ranganath, R. M., & Nagashree, N. R. (2001) · International review of cytology · doi:10.1016/s0074-7696(01)02005-8 · Cited by 81
Hypoxia selects for androgen independent LNCaP cells with a more malignant geno‐ and phenotype
Butterworth, K. T., McCarthy, H. O., Devlin, A. H., Ming, L., Robson, T., McKEOWN, S. R., & Worthington, J. (2008) · International Journal of Cancer · doi:10.1002/ijc.23418 · Cited by 72
“A number of groups have reported that hypoxia-induced apoptosis occurs mainly through mitochondrial death pathways, which can be inhibited by Bcl-2.”
BackgroundOh, S. Y., Kwon, H.-C., Kim, S.-H., Jang, J. S., Kim, M. C., Kim, K. H., Han, J., Kim, C. O., Kim, S., Jeong, J., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-123 · Cited by 74
“The hypoxic/anoxic induction of p53 selects for tumor cells that lack functional p53, and hence evidence diminished apoptotic potential [7].”
BackgroundExpression of hypoxia‐inducible factor‐1α in esophageal squamous cell carcinoma
Matsuyama, T., Nakanishi, K., Hayashi, T., Yoshizumi, Y., Aiko, S., Sugiura, Y., Tanimoto, T., Uenoyama, M., Ozeki, Y., & Maehara, T. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00025.x · Cited by 69
Kietzmann, T., Knabe, W., & Schmidt‐Kastner, R. (2001) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s004060170037 · Cited by 74
“First, hypoxia is a strong inducer of p53 in tumors; in this way hypoxia in rapidly growing tumors with poor vascularization provided a physiological pressure for the expansion of variant tumor cells with p53 mutations inactivating its apoptotic function (Graeber et al., 1996).”
BackgroundHypoxia-Inducible Regulation of a Prodrug-Activating Enzyme for Tumor-Specific Gene Therapy
Shibata, T., Giaccia, A. J., & Brown, J. M. (2002) · Neoplasia · doi:10.1038/sj.neo.7900189 · Cited by 78
Self-citationEndogenous markers of hypoxia/anaerobic metabolism and anemia in primary colorectal cancer
Koukourakis, M. I., Giatromanolaki, A. N., Polychronidis, A., Simopoulos, C., Gatter, K. C., Harris, A. L., & Sivridis, E. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00220.x · Cited by 77
Zhou, Y.-D., Kim, Y.-P., Mohammed, K. A., Jones, D. K., Muhammad, I., Dunbar, D. C., & Nagle, D. G. (2005) · Journal of Natural Products · doi:10.1021/np050029m · Cited by 72
Connor, J. H., Naczki, C., Koumenis, C., & Lyles, D. S. (2004) · Journal of Virology · doi:10.1128/jvi.78.17.8960-8970.2004 · Cited by 72
“Hypoxic stress can also select for the survival of cancer cells that are deficient in p53 function (16), leading to the expansion of cells that are more resistant to conventional cancer therapies.”
BackgroundAutocrine signaling in carcinoma: VEGF and the α6β4 integrin
Mercurio, A. M., Bachelder, R. E., Bates, R. C., & Chung, J. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2003.09.016 · Cited by 83
“In other terms, hypoxia selects for the survival of p53 mutant cells [8,12].”
BackgroundIdentification of a Mouse Thiamine Transporter Gene as a Direct Transcriptional Target for p53
Lo, P., Chen, J.-Y., Tang, P.-P., Lin, J., Lin, C.-H., Su, L.-T., Wu, C.-H., Chen, T.-L., Yang, Y., & Wang, F.-F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104701200 · Cited by 72
Hypoxia Suppression of Bim and Bmf Blocks Anoikis and Luminal Clearing during Mammary Morphogenesis
Whelan, K. A., Caldwell, S. A., Shahriari, K. S., Jackson, S. R., Franchetti, L. D., Johannes, G. J., & Reginato, M. J. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0353 · Cited by 70
“Although the mechanism linking hypoxia to poor prognosis is unclear, cells expressing HIF-1 are able to escape hypoxia-induced cell death and acquire sustained resistance to apoptotic signals (Graeber et al., 1996).”
BackgroundHypoxia‐induced pathways in breast cancer
Goonewardene, T. I., Sowter, H. M., & Harris, A. L. (2002) · Microscopy Research and Technique · doi:10.1002/jemt.10175 · Cited by 71
“In an experimental model, cells found to be resistant to p53-mediated apoptosis grew selectively in hypoxic areas (Graeber et al., 1996; Hockel et al., 1999).”
BackgroundSuppressing Mitochondrial Respiration Is Critical for Hypoxia Tolerance in the Fetal Growth Plate
Yao, Q., Khan, M. P., Merceron, C., LaGory, E. L., Tata, Z., Mangiavini, L., Hu, J., Vemulapalli, K., Chandel, N. S., Giaccia, A. J., et al. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.04.029 · Cited by 76
Self-citationHypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer
Zhu, Y., Denhardt, D. T., Cao, H., Sutphin, P. D., Koong, A. C., Giaccia, A. J., & Le, Q. (2005) · Oncogene · doi:10.1038/sj.onc.1208800 · Cited by 79
“…chemotherapy and radiotherapy (Brown and Giaccia, 1998), increases malignant tumor progression (Teicher et al., 1990; Young and Hill, 1990; Graeber et al., 1996), enhances tumor cell invasion and metastasis (Le et al., 2004), and is prognostic for tumor control by conventional treatment…”
BackgroundSelf-citationTumor hypoxia, p53, and prognosis in cervical cancers
Haensgen, G., Krause, U., Becker, A., Stadler, P. F., Lautenschlaeger, C., Wohlrab, W., Rath, F. W., Molls, M., & Dunst, J. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01523-1 · Cited by 83
Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Moore, J. S., Koblish, H. K., Lee, J. J., Lord, E. M., Trinchieri, G., et al. (1999) · PubMed · Cited by 75
Self-citationTreating cancer by inhibiting angiogenesis: new hopes and potential pitfall
Rak, J. W., & Kerbel, R. S. (1996) · Cancer and Metastasis Reviews · doi:10.1007/bf00437476 · Cited by 71
LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency
O’Connor, M. N., Kallenberg, D. M., Camilli, C., Pilotti, C., Dritsoula, A., Jackstadt, R., Bowers, C., Watson, H. A., Alatsatianos, M., Ohme, J., et al. (2021) · Med · doi:10.1016/j.medj.2021.10.002 · Cited by 73
Proteomic Analysis of Plasma Membrane from Hypoxia-Adapted Malignant Melanoma
Stockwin, L. H., Blonder, J., Bumke, M. A., Lucas, D. A., Chan, K. C., Conrads, T. P., Issaq, H. J., Veenstra, T. D., Newton, D. L., & Rybak, S. M. (2006) · Journal of Proteome Research · doi:10.1021/pr0601739 · Cited by 70
Fokas, E., McKenna, W. G., & Muschel, R. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9394-4 · Cited by 74
“These can include decreased proliferation [47], altered cell cycle kinetics such as G1/S-phase arrest [40], reduced apoptotic rates [48–50], clonal selection and clonal expansion towards an aggressive phenotype [12], and increased DNA damage repair efficiency [51].”
BackgroundAnti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice
El-Azab, M. F., Hishe, H. Z., Moustafa, Y. M., & El‐Awady, E. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.11.008 · Cited by 70
Predicting Recurrence After Radiotherapy in Head and Neck Cancer
Begg, A. C. (2012) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2011.12.002 · Cited by 77
The role of functional and molecular imaging in cancer drug discovery and development
Seddon, B. M., & Workman, P. (2003) · British Journal of Radiology · doi:10.1259/bjr/27373639 · Cited by 80
“Furthermore, it acts as a selective pressure for the development of a more malignant tumour phenotype [90], leading to enhanced tumour growth and progression [91].”
BackgroundInactivation of p53 and Retinoblastoma Family Pathways in Canine Osteosarcoma Cell Lines
Levine, R. A., & Fleischli, M. A. (2000) · Veterinary Pathology · doi:10.1354/vp.37-1-54 · Cited by 70
Li, Y., Wang, H., Oosterwijk, E., Tu, C., Shiverick, K. T., Silverman, D. N., & Frost, S. C. (2009) · Cancer Investigation · doi:10.1080/07357900802653464 · Cited by 70
He, F., Deng, X., Wen, B., Liu, Y., Sun, X., Xing, L., Minami, A., Huang, Y., Chen, Q., ZANZONICO, P. B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0677 · Cited by 70
How to overcome (and exploit) tumor hypoxia for targeted gene therapy
Greco, O., Marples, B., Joiner, M. C., & Scott, S. D. (2003) · Journal of Cellular Physiology · doi:10.1002/jcp.10374 · Cited by 77
“1; Yao et al., 1995; Graeber et al., 1996). p53 accumulated under hypoxia and was required for induction of apoptosis.”
BackgroundATM&A Key Determinant of Multiple Cellular Responses to Irradiation
Kastan, D.-S. L. M. B., Lim, D.-S., & Seong-Tae, K. (2001) · Acta Oncologica · doi:10.1080/02841860152619089 · Cited by 80
Hasan, N., Adams, G., Joiner, M., Marshall, J., & Hart, I. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.299 · Cited by 68
“However, this is not a straightforward issue, as Graeber et al (1996) have reported that p53 mutant cells are more resistant than cells with a p53 wild-type phenotype to hypoxia-induced apoptosis; this therefore seems contrary to our observations as HT29 is known to be mutant (e.g. Lawrence et al,…”
ResultReview: The molecular regulation of apoptosis and implications for radiation oncology
K. R. BLANK, M. S. R. (1997) · International Journal of Radiation Biology · doi:10.1080/095530097143789 · Cited by 70
Tan, Q., Saggar, J. K., Yu, M., Wang, M., & Tannock, I. F. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000131 · Cited by 73
Müller, P., Češková, P., & Vojtesek, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m412767200 · Cited by 75
Walenta, S., Snyder, S. A., Haroon, Z. A., Braun, R. D., Amin, K., Brizel, D. M., Mueller‐Klieser, W., Chance, B., & Dewhirst, M. W. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01700-x · Cited by 69
Box, A. H., & Demetrick, D. J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh274 · Cited by 81
Horiuchi, A., Hayashi, T., Kikuchi, N., Hayashi, A., Fuseya, C., Shiozawa, T., & Konishi, I. (2012) · International Journal of Cancer · doi:10.1002/ijc.27448 · Cited by 73
Sohda, M., Ishikawa, H., Masuda, N., Kato, H., Miyazaki, T., Nakajima, M., Fukuchi, M., Manda, R., Fukai, Y., Sakurai, H., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20215 · Cited by 74
Bergström, S. H., Hammarsten, P., Wikström, P., & Bergh, A. R. J. (2006) · The Prostate · doi:10.1002/pros.20473 · Cited by 69
“Hypothetically, as tumor hypoxia has recently been shown to make tumors more aggressive and metastatic [22,23], it is also possible that castration induced tumor hypoxia that fails to kill a sufficient number of tumor cells could instead make the tumor more aggressive.”
Exercise and the Tumor Microenvironment: Potential Therapeutic Implications
Wiggins, J. M., Opoku‐Acheampong, A. B., Baumfalk, D. R., Siemann, D. W., & Behnke, B. J. (2017) · Exercise and Sport Sciences Reviews · doi:10.1249/jes.0000000000000137 · Cited by 74
Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein
Yin, H. H., & Hamilton, A. D. (2004) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2003.09.096 · Cited by 69
Mizutani, A., Furukawa, T., Adachi, Y., Ikehara, S., & Taketani, S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111431200 · Cited by 79
Iron and liver cancer: an inseparable connection
Hino, K., Yanatori, I., Hara, Y., & Nishina, S. (2021) · FEBS Journal · doi:10.1111/febs.16208 · Cited by 75
Pneumoconiosis-related Lung Cancers
Katabami, M., Dosaka‐Akita, H., Honma, K., SAITOH, Y., 木村, 清., UCHIDA, Y., Mikami, H., Ohsaki, Y., Kawakami, Y., & Kikuchi, K. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.1.9906138 · Cited by 68
Lesser, M. P., & Barry, T. M. (2003) · Journal of Experimental Marine Biology and Ecology · doi:10.1016/s0022-0981(03)00141-2 · Cited by 76
Cheng, J., Zhou, W. J., Warner, G. M., Knudsen, B. E., Garovic, V. D., Gray, C., Lerman, L. O., Platt, J. L., Romero, J. C., Textor, S. C., et al. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.90439.2008 · Cited by 68
Genes commonly upregulated by hypoxia in human breast cancer cells MCF-7 and MDA-MB-231
Bando, H., Toi, M., Kitada, K., & Koike, M. (2003) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(03)00098-2 · Cited by 74
Ozone Therapy for Tumor Oxygenation: a Pilot Study
Clavo, B., Pérez, J. L., López, L., Suárez, G., Lloret, M., Rodríguez, V., Macías, D., Santana, M. C., Hernández, M. A., Martín-Oliva, R., et al. (2004) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/neh009 · Cited by 69
“This results in additional resistance to radiotherapy and chemotherapy ( 2 ) and further increase in angiogenesis and a more aggressive tumor potential (3–5).”
Kuninaka, S., Ichinose, Y., Koja, K., & Toh, Y. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1367 · Cited by 71
Heterogeneity of tumor oxygenation: relationship to tumor necrosis, tumor size, and metastasis
Jaeger, K. D., Moreno-Merlo, F., Kavanagh, M.-C., Fyles, A., Hedley, D. W., & Hill, R. P. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00323-x · Cited by 68
Giardina, C. A., & Inan, M. S. (1998) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(97)00140-7 · Cited by 74
Tirapazamine: Prototype for a novel class of therapeutic agents targeting tumor hypoxia
Gandara, D. R., Lara, P. N., Goldberg, Z., Le, Q., Mack, P., Lau, D. H., & Gumerlock, P. H. (2002) · Seminars in Oncology · doi:10.1053/sonc.2002.31531 · Cited by 72
Jang, A., & Hill, R. P. (1997) · Clinical & Experimental Metastasis · doi:10.1023/a:1018470709523 · Cited by 68
“Similarly, Graeber et al. [ 8 ] have demonstrated that the microenvironmental conditions in tumors, notably hypoxia, may select for cells without a normal functioning p53 gene, and therefore more aggressive phenotypes.”
BackgroundMatthew, E. M., Hart, L. S., Astrinidis, A., Navaraj, A., Dolloff, N. G., Dicker, D. T., Henske, E. P., & El-Deiry, W. S. (2009) · Cell Cycle · doi:10.4161/cc.8.24.10800 · Cited by 67
“Hypoxia induces expression of the p53 protein(9,10) and acts as a selective pressure for the elimination of cells with wild-type p53 and expansion of cells with mutant or inactive p53 protein.(10,11) p53 induced by hypoxic conditions is unable to upregulate its established transcriptional targets, due to a failure to…”
BackgroundHypoxia: syndicating triple negative breast cancer against various therapeutic regimens
Srivastava, N., Usmani, S. S., Subbarayan, R., Saini, R., & Pandey, P. K. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1199105 · Cited by 72
“In addition, hypoxic conditions favor the selection of p53 mutant cells having elevated levels of bcl-2, which is a well-known inhibitor of apoptosis, thus causing the decline in the p53 and bcl-2 ratio (p53/bcl-2), which further increases the mutation rates in clone populations (59, 60).”
BackgroundPeng, S., Chou, S., & Hsu, H. (1998) · Journal of Hepatology · doi:10.1016/s0168-8278(98)80014-7 · Cited by 70
The role of hypoxia in pulmonary vascular diseases: a perspective
Voelkel, N. F., Mizuno, S., & Bogaard, H. J. (2013) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00335.2012 · Cited by 75
“Hypoxia is a key factor in tumor progression; it regulates apoptosis [selection of populations that are resistant to apoptosis (28)], cell proliferation, and angiogenesis, and it impairs DNA repair pathways (13) and induces autophagy (67) and the anaerobic metabolic switch (70).”
BackgroundNocentini, A., Trallori, E., Singh, S., Lomelino, C. L., Bartolucci, G., Mannelli, L. D. C., Ghelardini, C., McKENNA, R. V., Gratteri, P., & Supuran, C. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01504 · Cited by 67
Selected cell and selective microenvironment in neoplastic development.
Rubin, H. (2001) · PubMed · Cited by 69
Combined analysis of p53 and RB pathways in epithelial ovarian cancer
Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., & Ogita, S. (2001) · Human Pathology · doi:10.1053/hupa.2001.27115 · Cited by 76
Hypoxia-inducible factor 1 alpha (HIF-1α) gene expression in human ovarian carcinoma
Nakayama, K., Kanzaki, A., Hata, K., Katabuchi, H., Okamura, H., Miyazaki, K., Fukumoto, M., & Takebayashi, Y. (2002) · Cancer Letters · doi:10.1016/s0304-3835(01)00762-5 · Cited by 76
Leri, A., Fiordaliso, F., Setoguchi, M., Limana, F., Bishopric, N. H., Kajstura, J., Webster, K. A., & Anversa, P. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64598-1 · Cited by 70
Bauer, A. J., Terrell, R., Doniparthi, N. K., Patel, A. D., Tuttle, R. M., Saji, M., Ringel, M. D., & Francis, G. L. (2002) · Thyroid · doi:10.1089/105072502320908286 · Cited by 69
“This process may be facilitated by loss of the tumor-suppressor protein p53, allowing tumors to escape cell-cycle regulation and increase resilience against stress-induced apoptosis (6,9).”
InfluentialCarbogen-induced changes in rat mammary tumour oxygenation reported by near infrared spectroscopy
Hull, E. L., Conover, D. L., & Foster, T. H. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690272 · Cited by 67
“Studies in cell culture support the suggestion that exposure to sustained hypoxia results in the selection of malignant cells expressing aggressive phenotypes (Graeber et al, 1996).”
BackgroundHypoxia and Metastasis in Breast Cancer
Chaudary, N., & Hill, R. P. (2007) · Breast Disease · doi:10.3233/bd-2007-26105 · Cited by 68
“On the other hand, hypoxia may also select for cells with enhanced hypoxia tolerance [55].”
Wang, F. (2015) · Medical Science Monitor · doi:10.12659/msm.893265 · Cited by 67
“The loss of p53 functions may cause a further acquisition of malignant tumor phenotypes, which could be promoted by tumor hypoxia [5].”
BackgroundScortegagna, M., Martin, R. J., Kladney, R. D., Neumann, R. G., & Arbeit, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3643 · Cited by 77
Improving the Radiosensitivity of Radioresistant and Hypoxic Glioblastoma
Sheehan, J. P., Shaffrey, M. E., Gupta, B., Larner, J. M., Rich, J. N., & Park, D. M. (2010) · Future Oncology · doi:10.2217/fon.10.123 · Cited by 71
“Demonstration of a low-oxygen environment favoring the survival of cells lacking p53 suggests that hypoxia plays a role in driving genomic instability [42,43].”
BackgroundWang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O., & Wilson, W. R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2296 · Cited by 69
“The potential for exploiting hypoxia as a target is reinforced by its association with multiple overlapping aspects of tumor progression including proliferation [2], invasiveness and metastasis [3], angiogenesis and vasculogenesis [4], resistance to cell death [5], the metabolic switch to aerobic glycolysis [6] and ge…”
BackgroundHommel, B., Sturny-Leclère, A., Volant, S., Veluppillai, N., Duchateau, M., Yu, C.-H. A., Hourdel, V., Varet, H., Matondo, M., Perfect, J. R., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007945 · Cited by 72
“In addition, resistance to apoptosis is 461 known in mammalian cells by the induction of apoptosis inhibitors such as IAP-2 [43,44] but 462 opposite results have been found with tumor cells [45].”
BackgroundBlagosklonny, M. V. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.6.1818 · Cited by 76
Hypoxia and Hypoxia Inducible Factors (HIF) as Important Regulators of Tumor Physiology
Acker, T., & Plate, K. H. (2004) · Cancer treatment and research · doi:10.1007/978-1-4419-8871-3_14 · Cited by 75
Kobayashi, N., Ishii, M., Ueno, Y., Kisara, N., Chida, N., Iwasaki, T., & Toyota, T. (1999) · Liver International · doi:10.1111/j.1478-3231.1999.tb00005.x · Cited by 66
Telomere Crisis, the Driving Force in Cancer Cell Evolution
Ishikawa, F. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1996.5928 · Cited by 69
Tumor Hypoxia Drives Genomic Instability
Tang, M., Bolderson, E., O'Byrne, K. J., & Richard, D. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626229 · Cited by 71
Chang, J., & Erler, J. T. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5915-6_3 · Cited by 83
Hypoxia-inducible factor 1α regulates lung adenocarcinoma cell invasion
Shyu, K., Hsu, F., Wang, M. J., Wang, B.-W., & Lin, S. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.01.013 · Cited by 65
Functional Analysis of p53 Binding under Differential Stresses
Krieg, A. J., Hammond, E. M., & Giaccia, A. J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00322-06 · Cited by 66
Self-citation
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.